Media Clarification

York, U.K. 27 January 2021:  Abingdon Health (AIM: ABDX) notes an article by the Financial Times published this afternoon and provides the following clarification.

In its admission document published on 15 December 2020, the Company noted that it had received an order on 25 September 2020 from the Department for Health & Social Care ("DHSC") for 1 million tests out of an initial framework agreement for 10 million tests. It also stated that there were no guarantees of further orders from the DHSC and that the DHSC had the option to cancel its outstanding orders if a CE mark had not been granted for home use by 25 December 2020.

On 29 December 2020, Abingdon Health reiterated that the DHSC had the option to cancel outstanding orders if a CE mark had not been granted for home use by 25 December 2020 and confirmed that in any event the contract expired on 14^th February 2021.

Subsequently, on 26 January, the Company announced that it had completed the delivery of its order of 1 million AbC-19 tests to the DHSC on 8 January 2021 and as noted previously, this contract will expire on 14 February 2021. The Company confirms that no further orders beyond the initial 1 million tests are expected to be placed under the DHSC contract. In-line with the Government's shift to a dynamic purchasing strategy, the Board expects that any future orders will be received via an application by the Company to future DHSC tender notices.  

Enquiries:

About Abingdon Health

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests. The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. Founded in 2008, Abingdon Health is headquartered in York, England.

https://www.abingdonhealth.com/

AbC-19TM Rapid Test

The Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.